Labiotech.eu

News and Trends 14 Sep 2020

The Funding Flow Between European and US Life Sciences

Funding is the lifeline of innovative ventures. In an increasingly uncertain environment, looking at the records of past investments can be essential for making sense of the future and getting closer to discovering what’s next for the life sciences industry. Exploring the differences between the two major groups of life sciences investors and the funding […]

September 14, 2020 - 11 minutesmins - By External Contributor

Interview 9 Sep 2020

Biotech Investment in Norway: An Alternative Approach

Norway has not typically been an attractive region for biotech investors, so when Masha Strømme set up her own investment firm in 2008, she had to take a slightly different approach to investment. Masha Strømme and her husband, Dag Strømme, run a family office together called Paacs Invest in the Oslo area, which funds and […]

September 9, 2020 - 6 minutesmins - By Helen Albert

Interview 2 Sep 2020

An Alzheimer’s Vaccine Challenged the Consensus for 25 Years

For decades, Alzheimer’s disease research focused on a hypothesis that has increasingly been contested. A team of scientists in Slovakia has been swimming against the tide since the beginning, going for an alternative approach that has only recently started gaining recognition. Research in Alzheimer’s disease has recently been plagued by intense disappointment. For over 25 […]

September 2, 2020 - 8 minutesmins - By Farhan Mitha

News and Trends 1 Sep 2020

Microbiome Therapies Threatened by Covid-19 Restrictions

Providers of microbiome therapies worldwide have been hit by pandemic restrictions on the harvest of stool samples. Though these measures are now loosening in France, key safety challenges remain for companies using fecal microbiota. Fecal microbiota transplants — procedures where healthy individuals donate their gut microbes to a patient — have changed how we treat […]

September 1, 2020 - 5 minutesmins - By Jonathan Smith

Inside Labiotech 28 Aug 2020

Content First: Labiotech’s Vision for 2020 and Beyond

2020 has been a challenging year for all of us. At Labiotech, we’re among the lucky businesses that weren’t affected too much by the pandemic. Our activity is online, and our team is used to working remotely, so fortunately, we were able to operate as normal during the lockdown. Still, a lot has happened in […]

August 28, 2020 - 7 minutesmins - By Joachim Eeckhout

Expert Advice 26 Aug 2020

Negotiating Early-Stage Biotech Valuation: VC vs Entrepreneur

There is usually a big disparity between investors and entrepreneurs regarding the valuation of an early-stage biotech company. How can both sides navigate this negotiation and reach a fair agreement? Many entrepreneurs in biotech might be puzzled when they get a low pre-money valuation for a product with high potential. Even when a product in […]

August 26, 2020 - 7 minutesmins - By External Contributor

unity biotechnology anti aging geroscience senolytics

News and Trends 25 Aug 2020

What Does Unity’s Phase II Fail Mean for European Anti-Aging Research?

A drug developed by the US firm Unity Biotechnology — designed to slow the aging process — recently proved a dud in phase II for the treatment of osteoarthritis. How is this high-profile setback affecting European biotechs developing anti-aging treatments? Aging is a complex, multi-faceted process that makes people vulnerable to a wide range of […]

August 25, 2020 - 6 minutesmins - By Jonathan Smith

Expert Advice 24 Aug 2020

Why a US Presence Can Help European Biotechs Get Ahead

While there is no doubt that Europe has a thriving biotech scene, it can really help a European company to succeed if it has a US presence. No one knows this better than Patricia Zilliox, CEO of French biotech company Eyevensys, who has lived and worked in the US for many years. Zilliox is French, […]

August 24, 2020 - 5 minutesmins - By Helen Albert

News and Trends 20 Aug 2020

Is Hepatitis D Healthcare Being Overlooked?

Despite the recent EU approval of the first hepatitis D treatment, low public awareness remains an obstacle to tackling this aggressive infection. Earlier this month, the peptide drug Hepcludex became the first drug greenlit for hepatitis D treatment in Europe. This was a conditional market authorization granted to the German company MYR Pharmaceuticals based on […]

August 20, 2020 - 4 minutesmins - By Jonathan Smith

Best in Biotech 19 Aug 2020

7 Biotech Books to Read in the Sun this Summer

Here are seven biotech books for the summer that will take you from CRISPR gene editing to the microbiome to pharma and economics, as well as sci-fi that takes biotech to space. The excitement of the summer break has been dampened somewhat by the ever-present threat of the Covid-19 pandemic. No matter where you end […]

August 19, 2020 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Aug 2020

Women’s Health Gains Traction as Bayer Pays €736M for UK Firm

Bayer’s recent €736M ($875M) acquisition of KaNDy Therapeutics could herald growing investor interest in women’s health – a historically neglected field in the biotech and pharma industry. Through this deal, Bayer has snapped up KaNDy Therapeutics’ first-in-class drug for treating hot flashes and night sweats, which often occur during the menopause. In a phase IIb […]

August 18, 2020 - 3 minutesmins - By Jonathan Smith

cancer vaccine virus ervaxx cell therapy

News and Trends 17 Aug 2020

CureVac Continues Covid-19 Vaccine Funding Frenzy with €180M IPO

The share price of CureVac has skyrocketed almost fivefold after the Covid-19 vaccine developer priced a Nasdaq IPO at €180M ($213M). The excitement around messenger RNA (mRNA) vaccines against Covid-19 could also benefit other players in mRNA therapeutics. CureVac’s IPO was priced at €14 ($16) per share, giving the German company a valuation of around […]

August 17, 2020 - 3 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The Funding Flow Between European and US Life Sciences

Biotech Investment in Norway: An Alternative Approach

An Alzheimer’s Vaccine Challenged the Consensus for 25 Years

Microbiome Therapies Threatened by Covid-19 Restrictions

Content First: Labiotech’s Vision for 2020 and Beyond

Negotiating Early-Stage Biotech Valuation: VC vs Entrepreneur

What Does Unity’s Phase II Fail Mean for European Anti-Aging Research?

Why a US Presence Can Help European Biotechs Get Ahead

Is Hepatitis D Healthcare Being Overlooked?

7 Biotech Books to Read in the Sun this Summer

Women’s Health Gains Traction as Bayer Pays €736M for UK Firm

CureVac Continues Covid-19 Vaccine Funding Frenzy with €180M IPO

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!